Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH3765 in Advanced Malignant Tumors
NCT05015309Phase 1Unknown
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SH3765 in triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), adenoid cystic carcinoma (ACC) and 4 more, sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity at 28 days and Maximum tolerated dose at 28 days. Status: unknown.
02
Drugs
SH3765
03
Conditions
triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)adenoid cystic carcinoma (ACC)prostate cancer (PCa)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05015309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05015309.